Document Detail


Toxicity of radiotherapy in patients with collagen vascular disease.
MedLine Citation:
PMID:  18506734     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: A diagnosis of collagen vascular disease (CVD) may predispose to radiotherapy (RT) toxicity. The objective of the current study was to identify factors that influence RT toxicity in the setting of CVD. METHODS: A total of 86 RT courses for 73 patients with CVD were delivered between 1985 and 2005. CVD subtypes include rheumatoid arthritis (RA; 33 patients), systemic lupus erythematosus (SLE; 13 patients), scleroderma (9 patients), dermatomyositis/polymyositis (5 patients), ankylosing spondylitis (4 patients), polymyalgia rheumatica/temporal arteritis (4 patients), Wegener granulomatosis (3 patients), and mixed connective tissue disorders (MCTD)/other (2 patients). Each patient with CVD was matched to 1 to 3 controls with respect to sex, race, site irradiated, RT dose (+/-2 Gray), and age (+/-5 years). RESULTS: There was no significant difference between CVD patients (65.1%) and controls (72.5%) experiencing any acute toxicity. CVD patients had a higher incidence of any late toxicity (29.1% vs 14%; P = .001), and a trend toward an increased rate of severe late toxicity (9.3% vs 3.7%; P = .079). RT delivered to the breast had increased risk of severe acute toxicity, whereas RT to the pelvis had increased risk of severe acute and late toxicity. RT administered in the setting of scleroderma carried a higher risk of severe late toxicity, whereas RT to SLE patients carried a higher risk of severe acute and late toxicity. CONCLUSIONS: Although generally well tolerated, RT in the setting of CVD appears to carry a higher risk of late toxicity. RT to the pelvis or in the setting of SLE or scleroderma may predispose to an even greater risk of severe toxicity. These issues should be considered when deciding whether to offer RT for these patients.
Authors:
Alexander Lin; Eyad Abu-Isa; Kent A Griffith; Edgar Ben-Josef
Related Documents :
18626304 - Primary sjögren syndrome in spain: clinical and immunologic expression in 1010 patients.
3581694 - Systemic lupus erythematosus: follow-up study of 148 patients. i: classification, clini...
18346514 - Clinical and laboratory characteristics and long-term outcome of pediatric systemic lup...
11971224 - Successful treatment of pure red cell aplasia with plasmapheresis in a patient with sys...
22250074 - Quality of life is impaired in association with the need for prolonged postoperative th...
23876994 - Right ventricular mechanical dyssynchrony and asymmetric contraction in hypoplastic hea...
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  Cancer     Volume:  113     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-07-28     Completed Date:  2008-09-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  648-53     Citation Subset:  AIM; IM    
Copyright Information:
(c) 2008 American Cancer Society
Affiliation:
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA. alexander.lin@jeffersonhospital.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Case-Control Studies
Collagen* / physiology
Connective Tissue Diseases / classification,  complications*,  epidemiology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasms / complications*,  epidemiology,  radiotherapy*
Polypharmacy
Radiation Injuries / epidemiology*
Time Factors
Vascular Diseases / classification,  complications*,  epidemiology
Chemical
Reg. No./Substance:
9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy.
Next Document:  Characterization of a new norfloxacin metabolite monitored during a bioequivalence study by means of...